



News Release

Source: Patheon Inc.
Website: www.patheon.com

Patheon Inc. Names Interim Head of Pharmaceutical Development Services Unit and Chief Scientific Officer

RESEARCH TRIANGLE PARK, North Carolina, (May 29, 2009) – Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has named Doug Mendenhall, Ph.D. as interim head of their Pharmaceutical Development Services Unit and will also carry the interim title of Chief Scientific Officer.

Dr. Mendenhall is working under contract until such time that a permanent President is named, but will be retained as an advisor to the company on an as-needed basis. Dr. Mendenhall is a 35 year veteran in the pharmaceutical industry, having held executive positions at Abbott, GlaxoSmithKline and most recently, Merck. He has spent his career leading pharmaceutical and pre-clinical development teams, contributing to the development and commercialization of an impressive list of blockbuster drugs. He holds a Ph.D. in Pharmaceutical Chemistry from the University of Kansas, a Masters in Medicinal Chemistry from the University of Kansas and Bachelors in Pharmacy from the University of Washington. He is also lean six sigma certified and a graduate from the Northwestern University / Kellogg Executive Management program.

“Doug brings a wealth of experience, maturity and strategic thinking to Patheon”, said Wes Wheeler, Chief Executive Officer & President. “With Doug on our Executive Committee, both leading the PDS unit and advising us on strategy, we will enable further strategic growth of our development services offering to clients. We look forward to Doug’s leadership, as we continue our search for a permanent President.”

ABOUT PATHEON

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical

packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated network strives to ensure that customer products can be launched with confidence globally.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts:

Mr. Wes Wheeler
President & Chief Executive Officer
Tel: (919) 226-3200
Email: wes.wheeler@patheon.com

Mr. Eric Evans
Chief Financial Officer
Tel: (919) 226-3200
Email: eric.evans@patheon.com